A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Mitoxantrone liposomal (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors CSPC Pharmaceutical Group
- 13 Dec 2022 Status changed from Not yet recruiting to withdrawn prior to enrolment.
- 13 Dec 2022 Planned End Date changed from 1 Aug 2028 to 8 Nov 2022.
- 13 Dec 2022 Planned primary completion date changed from 1 Dec 2024 to 8 Nov 2022.